ImmuCell Corporation (ICCC) Gross Margin
- Gross margin · 12 months: Value 40.32%; Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 40.32% | Gross profit / revenue. Period ending 2026-06-30. $12.37M ÷ $30.68M × 100 ≈ 40.32% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 12.37M USD | Gross Profit |
| Revenue | 30.68M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | $12.37M | $30.68M | (m) | 40.32% |
| 2026-03-31 | $12.75M | $29.93M | (m) | 42.59% |
| 2025-12-31 | $11.45M | $27.64M | (m) | 41.40% |
| 2025-09-30 | $11.37M | $27.77M | (m) | 40.93% |
| 2025-06-30 | $10.59M | $28.27M | $17.69M | 37.44% |
| 2025-03-31 | $9.00M | $27.30M | $18.30M | 32.96% |
| 2024-12-31 | $7.94M | $26.49M | $18.55M | 29.97% |
| 2024-09-30 | $6.37M | $23.84M | $17.47M | 26.71% |
| 2024-06-30 | $6.05M | (m) | $17.17M | (m) |
| 2024-03-31 | $5.86M | (m) | $15.42M | (m) |
| 2023-12-31 | $3.87M | $17.47M | $13.60M | 22.15% |
| 2023-09-30 | $3.60M | $16.29M | $12.68M | 22.13% |
| 2023-06-30 | $4.18M | (m) | $11.50M | (m) |
| 2023-03-31 | $4.85M | (m) | $11.17M | (m) |
| 2022-12-31 | $7.65M | (m) | $10.92M | (m) |
| 2022-09-30 | $9.22M | $20.10M | $10.88M | 45.86% |
| 2022-06-30 | $9.79M | (m) | $10.67M | (m) |
| 2022-03-31 | $10.16M | (m) | $10.98M | (m) |
| 2021-12-31 | $8.66M | (m) | $10.59M | (m) |
| 2021-09-30 | $7.72M | (m) | $9.83M | (m) |
| 2021-06-30 | $7.02M | (m) | $9.09M | (m) |
| 2021-03-31 | $6.23M | (m) | $8.31M | (m) |
| 2020-12-31 | $6.86M | (m) | $8.48M | (m) |
| 2020-09-30 | $7.08M | (m) | $8.15M | (m) |
| 2020-06-30 | $6.81M | (m) | $7.67M | (m) |
| 2020-03-31 | $6.77M | (m) | $7.45M | (m) |
| 2019-12-31 | $6.74M | (m) | $6.98M | (m) |
| 2019-09-30 | $6.30M | (m) | $6.73M | (m) |
| 2019-06-30 | $5.80M | (m) | $6.41M | (m) |
| 2019-03-31 | $6.04M | (m) | $6.48M | (m) |
| 2018-12-31 | $5.19M | (m) | $5.79M | (m) |
| 2018-09-30 | $5.01M | (m) | (m) | (m) |
| 2018-06-30 | $4.99M | (m) | (m) | (m) |
| 2018-03-31 | $4.43M | (m) | (m) | (m) |
| 2017-12-31 | $5.22M | (m) | (m) | (m) |
| 2017-09-30 | $5.23M | (m) | (m) | (m) |
| 2017-06-30 | $5.50M | (m) | (m) | (m) |
| 2017-03-31 | $5.82M | (m) | (m) | (m) |
| 2016-12-31 | $5.42M | (m) | (m) | (m) |
| 2016-09-30 | $5.86M | (m) | (m) | (m) |
| 2016-06-30 | $6.27M | (m) | (m) | (m) |
| 2016-03-31 | $6.16M | (m) | (m) | (m) |
| 2015-12-31 | $6.25M | (m) | (m) | (m) |
| 2015-09-30 | $5.94M | (m) | (m) | (m) |
| 2015-06-30 | $5.40M | (m) | (m) | (m) |
| 2015-03-31 | $5.15M | (m) | (m) | (m) |
| 2014-12-31 | $4.45M | (m) | (m) | (m) |
| 2014-09-30 | $3.71M | (m) | (m) | (m) |
| 2014-06-30 | $3.25M | (m) | (m) | (m) |
| 2014-03-31 | $3.16M | (m) | (m) | (m) |
| 2013-12-31 | $3.06M | (m) | (m) | (m) |
| 2013-09-30 | $3.20M | (m) | (m) | (m) |
| 2013-06-30 | $3.21M | (m) | (m) | (m) |
| 2013-03-31 | $3.10M | (m) | (m) | (m) |
| 2012-12-31 | $3.05M | (m) | (m) | (m) |
| 2012-09-30 | $3.03M | (m) | (m) | (m) |
| 2012-06-30 | $2.93M | (m) | (m) | (m) |
| 2012-03-31 | $2.96M | (m) | (m) | (m) |
| 2011-12-31 | $2.81M | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) |
| 2010-12-31 | $2.30M | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) |
| 2009-12-31 | $2.40M | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |